title: Did Pfizer Overpay For Yet Another Acquisition?
source: SeekingAlpha
date: 2025-10-18
url: https://finnhub.io/api/news?id=7087527d5498ab0d0bb46fb5e2143b4af4ff288c010aa3dd60750f793e5df6f7
Pfizer enters the obesity drug market with a reasonably valued deal, while valuation remains attractive and technicals show stability. See why PFE stock is a hold.
